DBV Technologies Stock Rises 2.85% to €3.54 Ahead of Two FDA Filings in 2026
French biotech company advances 2.85% to €3.54 in mid-morning trading, alongside a 1.58% increase in the CAC 40. The stock is trading close to its 50-day moving average and remains well above its 200-day moving average at €2.80. The year 2026 is set to be pivotal in terms of regulatory developments for its anti-allergen patch, Viaskin Peanut.
A Busy Regulatory Calendar for Viaskin Peanut
DBV Technologies' schedule is marked by upcoming U.S. regulatory deadlines. The biotech has confirmed its plans to submit two Biologics License Applications this year to the FDA, one for children aged 4 to 7, and another for toddlers aged 1 to 3, as reiterated in its early May communication. The company also plans to initiate a Phase 2 study in infants aged 6 to 12 months. Financially, the company reported a cash position of $229 million as of March 31, 2026, following the full exercise of warrants from the private placement in March 2025. This funding is expected to cover expenses until the second quarter of 2027, according to the company's published documents. The net loss for the first quarter widened to $47.6 million, reflecting increased R&D spending in preparation for regulatory submissions. The next key date on the calendar is the Mixed General Meeting on June 3.
Stock Price Caught Between 50-Day MA and €3.85 Resistance
The stock is trading at €3.54, just below its 50-day moving average of €3.60. Crossing this short-term benchmark is necessary to reignite momentum towards the resistance level at €3.85, which represents an approximate 8.8% increase from the current price. The 200-day moving average at €2.80 remains significantly lower, indicating that the long-term trend is still bullish with an annual performance of 121.6%. The RSI at 46 indicates a lack of directional momentum following a 7.8% decline over three months. The next important date for shareholders is the General Meeting on June 3, 2026.
